AU2007278054B2 - Pharmaceutical compositions comprising CCL2 and use of same for the treatment of inflammation - Google Patents

Pharmaceutical compositions comprising CCL2 and use of same for the treatment of inflammation Download PDF

Info

Publication number
AU2007278054B2
AU2007278054B2 AU2007278054A AU2007278054A AU2007278054B2 AU 2007278054 B2 AU2007278054 B2 AU 2007278054B2 AU 2007278054 A AU2007278054 A AU 2007278054A AU 2007278054 A AU2007278054 A AU 2007278054A AU 2007278054 B2 AU2007278054 B2 AU 2007278054B2
Authority
AU
Australia
Prior art keywords
ccl2
cells
diseases
cell
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007278054A
Other languages
English (en)
Other versions
AU2007278054A1 (en
Inventor
Liat Flaishon
Idit Shachar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of AU2007278054A1 publication Critical patent/AU2007278054A1/en
Application granted granted Critical
Publication of AU2007278054B2 publication Critical patent/AU2007278054B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AU2007278054A 2006-07-24 2007-06-28 Pharmaceutical compositions comprising CCL2 and use of same for the treatment of inflammation Ceased AU2007278054B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83260006P 2006-07-24 2006-07-24
US60/832,600 2006-07-24
PCT/IL2007/000806 WO2008012796A2 (en) 2006-07-24 2007-06-28 Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation

Publications (2)

Publication Number Publication Date
AU2007278054A1 AU2007278054A1 (en) 2008-01-31
AU2007278054B2 true AU2007278054B2 (en) 2012-11-22

Family

ID=38981868

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007278054A Ceased AU2007278054B2 (en) 2006-07-24 2007-06-28 Pharmaceutical compositions comprising CCL2 and use of same for the treatment of inflammation

Country Status (7)

Country Link
US (2) US7919077B2 (cg-RX-API-DMAC10.html)
EP (1) EP2056857B1 (cg-RX-API-DMAC10.html)
JP (1) JP2009544690A (cg-RX-API-DMAC10.html)
AU (1) AU2007278054B2 (cg-RX-API-DMAC10.html)
CA (1) CA2658719A1 (cg-RX-API-DMAC10.html)
ES (1) ES2434039T3 (cg-RX-API-DMAC10.html)
WO (1) WO2008012796A2 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2658719A1 (en) * 2006-07-24 2008-01-31 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
US20120070449A1 (en) 2009-05-28 2012-03-22 Yeda Research And Development Co. Ltd. Methods of treating inflammation
CN101829075B (zh) * 2010-04-27 2011-07-20 中国人民解放军第三军医大学第一附属医院 苦柯胺a和苦柯胺b的用途
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
EP3288587A4 (en) * 2015-04-29 2018-09-12 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
CN108697804B (zh) * 2015-10-05 2022-11-15 德克萨斯州立大学董事会 用于软骨损伤的检测和治疗的微米和纳米装置
KR102066149B1 (ko) * 2018-08-17 2020-01-14 고려대학교 산학협력단 Ccl2를 유효성분으로 포함하는 임신촉진용 조성물
KR102154235B1 (ko) * 2019-02-11 2020-09-09 고려대학교 산학협력단 Ccl2를 유효성분으로 포함하는 산유량 증가용 조성물, 및 유방염 예방 또는 치료용 약학적 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271093A (ja) * 1992-03-30 1993-10-19 Toray Ind Inc 血管内皮細胞増殖剤
WO2000006203A1 (en) * 1998-07-28 2000-02-10 Technion Research And Development Foundation Ltd. Dna cytokine vaccines and use of same for protective immunity against multiple sclerosis
WO2007021807A1 (en) * 2005-08-12 2007-02-22 Schering Corporation Mcp1 fusions
WO2007105224A1 (en) * 2006-03-16 2007-09-20 Protagonists Ltd. Combination of cytokine and cytokine receptor for altering immune system functioning

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184235B1 (en) * 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
GB0016138D0 (en) * 2000-06-30 2000-08-23 Novartis Ag Organic compounds
DE60027419D1 (de) * 2000-07-06 2006-05-24 Deutsches Krebsforsch Regulatorische Sequenzen des humanen MCP-1 Gens
US7601692B2 (en) * 2000-11-28 2009-10-13 Compugen Ltd. MCP-1 splice variants and methods of using same
TWI245761B (en) * 2001-03-01 2005-12-21 Telik Inc Antagonists of MCP-1 function and methods of use thereof
EP1542724A4 (en) * 2002-08-19 2005-10-19 Abgenix Inc ANTIBODIES AGAINST THE MONOCYTE 1 CHIMIOATTRACTIVE PROTEIN (MCP-1) AND USES THEREOF
JP4601936B2 (ja) * 2002-10-29 2010-12-22 株式会社ミノファーゲン製薬 Ｍｃｐ−１産生抑制のための薬学的組成物
AR046594A1 (es) * 2003-10-16 2005-12-14 Applied Research Systems Usos terapeuticos de variantes de quemoquina
US20050232923A1 (en) * 2003-11-05 2005-10-20 Li Yan Methods and compositions for treating MCP-1 related pathologies
CA2658719A1 (en) * 2006-07-24 2008-01-31 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271093A (ja) * 1992-03-30 1993-10-19 Toray Ind Inc 血管内皮細胞増殖剤
WO2000006203A1 (en) * 1998-07-28 2000-02-10 Technion Research And Development Foundation Ltd. Dna cytokine vaccines and use of same for protective immunity against multiple sclerosis
WO2007021807A1 (en) * 2005-08-12 2007-02-22 Schering Corporation Mcp1 fusions
WO2007105224A1 (en) * 2006-03-16 2007-09-20 Protagonists Ltd. Combination of cytokine and cytokine receptor for altering immune system functioning

Also Published As

Publication number Publication date
US20110165116A1 (en) 2011-07-07
US20090239799A1 (en) 2009-09-24
EP2056857B1 (en) 2013-08-21
ES2434039T3 (es) 2013-12-13
AU2007278054A1 (en) 2008-01-31
WO2008012796A3 (en) 2009-04-09
EP2056857A2 (en) 2009-05-13
JP2009544690A (ja) 2009-12-17
WO2008012796A2 (en) 2008-01-31
US7919077B2 (en) 2011-04-05
EP2056857A4 (en) 2011-02-16
CA2658719A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
US20110165116A1 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
US7354575B2 (en) Method and pharmaceutical composition for treating inflammation
Schinocca et al. Role of the IL-23/IL-17 pathway in rheumatic diseases: an overview
Kim et al. A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis
Martin et al. Increased expression of CCL2 in insulin-producing cells of transgenic mice promotes mobilization of myeloid cells from the bone marrow, marked insulitis, and diabetes
Gerdes et al. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis
Garcia et al. Suppression of collagen-induced arthritis by oral or nasal administration of type II collagen
US5624938A (en) Use of chloroquine to treat multiple sclerosis
Berghmans et al. Rescue from acute neuroinflammation by pharmacological chemokine-mediated deviation of leukocytes
Billiau et al. Biologic role of interferon beta in multiple sclerosis
SK91696A3 (en) Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity
Martı́nez et al. Type IV phosphodiesterase inhibition in experimental allergic encephalomyelitis of Lewis rats: sequential gene expression analysis of cytokines, adhesion molecules and the inducible nitric oxide synthase
US12398369B2 (en) Purified double negative T cell and preparation and use thereof
Kimura et al. The absence of interleukin-6 enhanced arsenite-induced renal injury by promoting autophagy of tubular epithelial cells with aberrant extracellular signal-regulated kinase activation
Koda et al. CCR9 axis inhibition enhances hepatic migration of plasmacytoid DCs and protects against liver injury
CN120899719A (zh) Sirt4-in-1在制备治疗自身免疫疾病的药物中的应用
CA2582471A1 (en) Type i interferon blocking agents for prevention and treatment of psoriasis
US20240325389A1 (en) New therapeutic targets with an anti-inflammatory and anti-interferon effect
Su et al. Cardiac injury progression in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection: a review
US20110136897A1 (en) Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders
CN111588840A (zh) 组蛋白去泛素化酶在制备治疗系统性红斑狼疮药物的应用
SEKO et al. RESTRICTED USAGE OF T‐CELL RECEPTOR Vα GENES IN INFILTRATING CELLS IN MURINE HEARTS WITH ACUTE MYOCARDITIS CAUSED BY COXSACKIE VIRUS B3
WO1998002173A1 (en) Method for treatment of systemic sclerosis and related fibrotic diseases
KR101324647B1 (ko) 다발성신경경화증의 치료 또는 예방용 조성물 및 이의 스크리닝 방법
US20090232834A1 (en) Methods and Agents to Treat Autoimmune Diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired